Alemtuzumab and CXCL9 Levels Predict Likelihood of Sustained Engraftment after Reduced-Intensity Conditioning HCT.
Ashley Geerlinks,Brooks Scull,Christa Krupski,Ryan Fleischmann,Michael A. Pulsipher,Mary Eapen,James A. Connelly,Catherine M. Bollard,Sung-Yun Pai,Christine N. Duncan,Leslie S. Kean,K. Scott Baker,Lauri M. Burroughs,Jeffrey R. Andolina,Shalini Shenoy,Philip Roehrs,Rabi Hanna,Julie-An Talano,Kirk R. Schultz,Elizabeth O. Stenger,Howard Lin,Adi Zoref-Lorenz,Kenneth L. McClain,Michael B. Jordan,Tsz-Kwong Man,Carl E. Allen,Rebecca A. Marsh Blood Advances（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper